This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v., Rheinisch-Westfaelische Technische Hochschule Aachen. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 4,924 
1 out of 16 
Years Active: 2020
Title: Innovative Contributions of Lea Christin Schenke
Introduction
Lea Christin Schenke, an accomplished inventor based in Holzgerlingen, Germany, has made significant strides in the field of biomedical innovations. With a focus on developing targeted therapies, her work contributes to the advancement of treatment options for various diseases, particularly cancer.
Latest Patents
Lea Christin Schenke holds a notable patent for an "Anti-CD89 cytotoxic complex." This invention involves complexes designed for targeting and eliminating human target cells by utilizing a first polypeptide that binds to the CD89 cellular surface receptor. This complex also includes a second polypeptide that comprises a toxic effector domain, preferably exotoxin A. The patent encompasses nucleic acid molecules encoding these complexes, vectors, and host cells, along with methods for their preparation. Importantly, her work aims to develop compositions and methodologies for treating diseases such as leukemia.
Career Highlights
Throughout her professional journey, Lea has contributed her expertise to renowned institutions. She worked at the Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., where she focused on applied research. Additionally, her tenure at the Rheinisch-Westfälische Technische Hochschule Aachen highlights her commitment to scientific advancement and innovation.
Collaborations
Lea Christin Schenke has had the opportunity to collaborate with notable individuals in her field, including Christoph Stein and Radoslav Mladenov. These partnerships emphasize the collaborative spirit of scientific research and development, which can lead to groundbreaking innovations.
Conclusion
Lea Christin Schenke's inventive contributions are poised to make a lasting impact on the healthcare sector, specifically in the treatment of cancer. Her patent for the Anti-CD89 cytotoxic complex showcases her commitment to developing effective therapies. As she continues to work in the field, her innovations will undoubtedly help shape future advancements in biomedical research and patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile